Doctor Karin Borges, Head of the Neurological Disorders and Metabolism Laboratory, studied Biology in at the University of Freiburg (Germany). Studying glutamate receptors in glial cells, she received a PhD in Neurobiology at Heidelberg University in 1994. She continued her education as a postdoctoral fellow at the Department of Pharmacology at Emory University studying the regulation of transcription of the glutamate receptor subunits, GluR1 and GluR4.

Since 2001, she has been interested in the morphological and functional changes involved in the development epilepsy as an instructor at Emory University, then as Assistant Professor at Texas Tech University (2005-2008) and since 2009 at UQ. Her long-term goal is to find new treatments for neurological disorders, including metabolic and anti-inflammatory approaches. To this end she has been receiving several grants from NHMRC, US philanthropic foundations and pharmaceutical industry for her laboratory work and clinical trials of her findings.

She has applied for several patents regarding triheptanoin as a new treatment for epilepsy and Amyotrophic Lateral Sclerosis(ALS)/Motore Neuron Disease (licensed). Currently, the laboratory is investigating the specific biochemical impairments in energy metabolism in epilepsy and ALS with the goal to develop scientifically validated new treatment approaches that target these specific impairments.